ARK Genomic Revolution ETFARKG

ARKG, the ARK Genomic Revolution ETF, is a publicly traded basket of biotechnology and genomics companies selected by an index methodology and then subjected to the issuer’s discretion. The fund’s mandate is to capture companies engaged in gene editing, diagnostics, therapeutics, and agricultural biology, but the actual portfolio is a living document that changes daily as issuers rebalance, securities enter or exit the eligible universe, and the index provider updates its rules. The fund’s ticker ARKG trades on major exchanges, and its price moves with the combined fortunes of its holdings, the fee it charges, and the liquidity conditions of small-cap biotech names. The issuer’s marketing frames these holdings as part of a “genomic revolution,” but the revolution’s logistics are handled by settlement systems, custody banks, and exchange plumbing that don’t care about revolutions. (source: Nasdaq market activity page for ARKG, https://www.nasdaq.com/market-activity/etf/arkg)

What ARKG actually holds is disclosed in the issuer’s daily portfolio filings and the index methodology documents filed with the SEC. The fund’s expense ratio of 0.75% is deducted daily, so the effective drag on returns is a continuous flow rather than a one-off levy. The fund’s assets under management and liquidity metrics are updated on the issuer’s website and exchange feeds, but the core tension remains: the fee is certain, the holdings are variable, and the “genomic revolution” is still being priced by a market that rebalances faster than most cells divide. (source: SEC EDGAR fund search for ARKG, https://www.sec.gov/edgar/search/#/q=ARKG)

The fund’s holdings are concentrated in a handful of genomics bellwethers, which means its fortunes rise and fall with a small group of stocks that can swing violently on clinical trial results or regulatory decisions. The issuer’s board and advisers are compensated to manage this concentration risk, but the fund’s unitholders ultimately absorb the volatility after the fee is taken. The SEC filings confirm the fund’s structure, the index methodology, and the fee schedule, but they do not guarantee the holdings will relative strength their benchmarks or that the fee will feel justified in hindsight. (source: FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/)

For a live chart and current price action, see the Nasdaq market activity page for ARKG, which tracks the fund’s intraday moves against its holdings and the broader biotech sector. The chart shows the fund’s price, volume, and spread, but it does not show the daily decisions that go into rebalancing the underlying basket or the management desks theatrics that precede fee adjustments. The fund’s liquidity is a function of its holdings’ liquidity, so during biotech sell-offs, ARKG can gap wider than its headline fee suggests. (source: Nasdaq market activity page for ARKG, https://www.nasdaq.com/market-activity/etf/arkg)

The fund’s prospectus and index methodology documents detail how holdings are selected, weighted, and reviewed, but the actual performance of the basket is not guaranteed by the issuer or the index provider. The fund’s 0.75% fee is disclosed upfront, but the cumulative effect of that fee over years is a silent companion to every basis point of alpha or beta. The SEC filings confirm the rules, the issuer confirms the fee, and the market confirms the price, but the fund’s investors confirm the outcome only after the fact. (source: SEC EDGAR fund search for ARKG, https://www.sec.gov/edgar/search/#/q=ARKG)